By increasing cAMP levels, depression has also become an attractive target for PDE4 inhibitors [168] and in this last decade, three compounds have entered clinical trials: BPN14770, which completed Phase II in 2021, GSK356278 and Roflumilast whose estimated primary completion date is October 2022. This evidence concerns the gene PDE4A and depressive disorder.